
  
    
      
        Synopsis_NNP
        
          Introduction_NNP
          A_DT complete_JJ understanding_NN of_IN the_DT genetic_JJ events_NNS
          involved_VBN in_IN breast_NN tumorigenesis_NNS and_CC their_PRP$ heterogeneity_NN
          in_IN relation_NN to_TO stage_VB specificity_NN will_MD be_VB critical_JJ to_TO the_DT
          development_NN of_IN successful_JJ treatments_NNS ._. This_DT laboratory_NN and_CC
          other_JJ workers_NNS recently_RB reported_VBD the_DT presence_NN of_IN a_DT novel_JJ
          LOH_NNP region_NN in_IN band_NN 18_CD p_NN 11_CD ._. 3_LS in_IN non-small_JJ cell_NN lung_NN
          carcinomas_NNS ,_, glioblastomas_NNS and_CC invasive_JJ breast_NN carcinomas_NNS
          [_NN 1_CD ,_, 2_CD ]_NN ._. This_DT current_JJ study_NN uses_VBZ informative_JJ loci_NN in_IN
          18_CD p_NN 11_CD ._. 3_LS to_TO investigate_VB the_DT stage_NN specificity_NN and_CC extent_NN
          of_IN molecular_JJ heterogeneity_NN exhibited_VBN by_IN this_DT locus_JJ in_IN
          breast_NN cancer_NN progression_NN ._. These_DT results_NNS are_VBP analyzed_VBN in_IN
          conjunction_NN with_IN other_JJ LOH_NNP data_NNS available_JJ for_IN markers_NNS on_IN
          3_CD p_NN ,_, 11_CD p_NN ,_, 13_CD q_NN ,_, 16_CD p_NN ,_, 17_CD p_NN ,_, and_CC 17_CD q_NN in_IN an_DT effort_NN to_TO place_VB
          chromosome_NN 18_CD p_NN alterations_NNS on_IN the_DT breast_NN cancer_NN
          progression_NN pathway_NN ._.
        
        
          Materials_NNS and_CC methods_NNS
          The_DT material_NN used_VBN in_IN this_DT study_NN ,_, consisting_VBG of_IN
          formalin-fixed_JJ ,_, paraffin-embedded_JJ tissue_NN from_IN the_DT
          archives_NNS of_IN the_DT Armed_NNP Forces_NNP Institute_NNP of_IN Pathology_NNP ,_, has_VBZ
          been_VBN previously_RB described_VBN [_NN 3_CD ]_NN ._. Tumors_NNP were_VBD selected_VBN at_IN
          random_JJ for_IN those_DT with_IN the_DT presence_NN of_IN lesions_NNS
          representing_VBG multiple_JJ stages_NNS of_IN breast_NN disease_NN within_IN
          individual_JJ patient_NN samples_NNS ._. Ninety-six_NNP foci_NN representing_VBG
          normal_JJ ,_, intraductal_NN and_CC infiltrating_VBG tumor_NN were_VBD
          microdissected_JJ from_IN 30_CD tumors_NNS ._. Matching_NNP normal_JJ and_CC tumor_NN
          DNA_NNP were_VBD subjected_VBN to_TO polymerase_NN chain_NN reaction_NN
          (_( PCR_NNP )_) -_: based_VBN LOH_NNP analysis_NN using_VBG two_CD 18_CD p_NN 11_CD ._. 3_LS markers_NNS
          (_( D_NNP 18_CD S_NNP 59_CD and_CC D_NNP 18_CD S_NNP 481_CD )_) and_CC one_CD 18_CD p_NN 11_CD ._. 2_LS marker_NN (_( D_NNP 18_CD S_NNP 452_CD )_) ._.
          Forward_NNP primers_NNS were_VBD synthesized_JJ with_IN either_DT a_DT
          fluorescent_NN FAM_NNP tag_NN (_( D_NNP 18_CD S_NNP 481_CD and_CC D_NNP 18_CD S_NNP 452_CD )_) or_CC a_DT
          fluorescent_NN TET_NNP tag_NN (_( D_NNP 18_CD S_NNP 59_CD )_) on_IN the_DT 5_CD '_POS end_NN ._. PCR_NNP reactions_NNS
          were_VBD performed_VBN in_IN 10_CD μl_NN with_IN aliquots_NNS of_IN normal_JJ and_CC tumor_NN
          DNA_NNP using_VBG a_DT PCR_NNP protocol_NN consisting_VBG of_IN 94_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_,
          55_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_, and_CC 72_CD °_NN C_NNP for_IN 1_CD min_NN for_IN a_DT total_NN of_IN 40_CD
          cycles_NNS ._. Horizontal_NNP ultrathin_NN ,_, high_JJ throughput_NN
          fluorescence-based_JJ DNA_NNP fragment_NN gel_NN electrophoresis_NNS
          (_( GTI-_NNP 9600_CD ;_: Genesys_NNP Technologies_NNPS ,_, Inc_NNP ,_, Sauk_NNP City_NNP ,_, WI_NNP ,_, USA_NNP )_)
          was_VBD applied_VBN to_TO the_DT separation_NN and_CC analysis_NN of_IN
          PCR-generated_NNP alleles_NNS as_RB previously_RB described_VBD [_NN 4_CD ]_NN ._.
          Allelic_NNP ratios_NNS were_VBD calculated_VBN and_CC expressed_VBN as_IN a_DT
          percentage_NN of_IN loss_NN of_IN intensity_NN for_IN the_DT tumor_NN allele_NN
          compared_VBN with_IN the_DT corresponding_JJ normal_JJ allele_NN (_( D-_NNP value_NN )_)
          after_IN normalization_NN ._.
        
        
          Results_NNS
          A_DT total_NN of_IN 96_CD foci_NN were_VBD analyzed_VBN for_IN LOH_NNP at_IN several_JJ
          polymorphic_JJ markers_NNS in_IN 18_CD p_NN 11_CD ._. 3_LS ._. The_DT overall_JJ frequency_NN of_IN
          LOH_NNP in_IN 18_CD p_NN 11_CD ._. 3_LS was_VBD 63_CD %_NN (_( 27_CD /_NN 43_CD )_) ._. When_WRB analyzed_VBN by_IN tumor_NN
          stage_NN ,_, LOH_NNP on_IN 18_CD p_NN was_VBD found_VBN in_IN 56_CD %_NN (_( 9_CD /_NN 16_CD )_) of_IN ductal_NN
          carcinoma_NN 
          in_IN situ_NN (_( DCIS_NNP )_) foci_NN ,_, 67_CD %_NN of_IN
          invasive_JJ ductal_NN carcinoma_NN (_( IDC_NNP )_) foci_NN (_( 14_CD /_NN 21_CD )_) ,_, and_CC 67_CD %_NN
          (_( 4_CD /_NN 6_CD )_) of_IN metastatic_JJ disease_NN ._. A_DT schematic_JJ diagram_NN of_IN these_DT
          results_NNS appears_VBZ in_IN Figure_NN 1_CD ._.
          We_PRP also_RB examined_VBD the_DT extent_NN of_IN heterogeneity_NN
          associated_VBN with_IN chromosome_NN 18_CD p_NN LOH_NNP (_( Fig_NNP ._. 2_LS )_) ._. In_IN tumors_NNS
          where_WRB information_NN was_VBD attainable_JJ for_IN two_CD or_CC more_JJR disease_NN
          stages_NNS ,_, 73_CD %_NN (_( 11_CD /_NN 15_CD )_) displayed_VBD a_DT pattern_NN of_IN classic_JJ clonal_NN
          progression_NN ._. LOH_NNP first_RB appeared_VBD in_IN the_DT DCIS_NNP stage_NN for_IN the_DT
          majority_NN ._. Four_CD tumors_NNS (_( 27_CD %_NN )_) were_VBD ,_, however_RB ,_, interestingly_RB
          identified_VBN with_IN genetic_JJ heterogeneity_NN for_IN chromosome_NN 18_CD p_NN
          events_NNS where_WRB DCIS-identified_NNP events_NNS were_VBD not_RB found_VBN in_IN
          associated_VBN invasive_JJ foci_NN ._. Genetic_JJ events_NNS involving_VBG
          chromosome_NN 18_CD p_NN sequences_NNS thus_RB do_VBP not_RB follow_VB a_DT classic_JJ
          progression_NN paradigm_NN in_IN 27_CD %_NN of_IN tumor_NN cases_NNS analyzed_VBD as_IN
          part_NN of_IN this_DT study_NN ._.
        
        
          Discussion_NNP
          Significant_JJ LOH_NNP on_IN chromosome_NN 18_CD p_NN 11_CD ._. 3_LS (_( 63_CD %_NN )_) suggests_VBZ
          the_DT presence_NN of_IN a_DT putative_JJ tumor_NN suppressor_NN gene_NN (_( s_VBZ )_) with_IN
          an_DT important_JJ role_NN in_IN the_DT pathogenesis_NNS of_IN breast_NN cancer_NN ._.
          These_DT measured_VBN allelic_JJ deletions_NNS represented_VBD alterations_NNS
          confined_VBN to_TO 18_CD p_NN 11_CD ._. 3_LS and_CC not_RB whole_JJ chromosome_NN 18_CD loss_NN
          based_VBN on_IN results_NNS using_VBG marker_NN D_NNP 18_CD S_NNP 452_CD ,_, although_IN the_DT
          presence_NN of_IN simultaneous_JJ but_CC independent_JJ LOH_NNP on_IN 18_CD q_NN was_VBD
          not_RB examined_VBN ._. It_PRP was_VBD discovered_VBN ,_, by_IN analyzing_VBG multiple_JJ
          foci_NN occurring_VBG simultaneously_RB within_IN individual_JJ tumors_NNS ,_,
          that_DT chromosome_NN 18_CD p_NN events_NNS occur_VBP at_IN a_DT significant_JJ
          frequency_NN (_( 56_CD %_NN )_) early_RB in_IN the_DT tumorigenic_JJ process_NN ,_, making_VBG
          LOH_NNP at_IN chromosome_NN 18_CD p_NN one_CD of_IN the_DT most_RBS common_JJ known_VBN events_NNS
          in_IN DCIS_NNP tumors_NNS ._. A_DT slightly_RB higher_JJR frequency_NN of_IN LOH_NNP in_IN IDC_NNP
          tumors_NNS (_( 67_CD %_NN )_) as_RB well_RB as_IN in_IN the_DT small_JJ number_NN of_IN metastatic_JJ
          samples_NNS studied_VBD further_JJ supports_VBZ this_DT early_JJ event_NN
          hypothesis_NNS ._. The_DT majority_NN (_( 73_CD %_NN )_) of_IN these_DT breast_NN tumors_NNS
          progressed_VBD in_IN a_DT clonal_NN fashion_NN ._. Four_CD cases_NNS (_( 27_CD %_NN )_) were_VBD ,_,
          however_RB ,_, representative_NN of_IN genetic_JJ heterogeneity_NN ._. Such_JJ
          heterogeneity_NN at_IN multiple_JJ loci_NN may_MD account_VB for_IN treatment_NN
          failure_NN ,_, and_CC a_DT combinatorial_NN histological_JJ and_CC genetic_JJ
          approach_NN with_IN sufficient_JJ information_NN on_IN survival_NN and_CC
          response_NN profiles_NNS may_MD provide_VB more_RBR effective_JJ disease_NN
          prevention_NN and_CC cure_VB in_IN the_DT future_NN ._.
        
      
      
        Full_NNP article_NN
        
          Introduction_NNP
          The_DT molecular_JJ pathogenetic_JJ pathway_NN of_IN breast_NN tumor_NN
          progression_NN is_VBZ not_RB yet_RB clearly_RB defined_VBN ._. Although_IN LOH_NNP at_IN
          chromosomes_NNS 1_CD ,_, 3_CD p_NN ,_, 6_CD q_NN ,_, 7_CD q_NN ,_, 8_CD p_NN ,_, 9_CD p_NN ,_, 10_CD q_NN ,_, 11_CD ,_, 13_CD q_NN ,_, 16_CD q_NN ,_, 17_CD ,_,
          18_CD q_NN ,_, 22_CD q_NN ,_, and_CC X_NNP have_VBP all_DT been_VBN reported_VBN [_NN 5_CD ,_, 6_CD ]_NN ,_, their_PRP$
          relationship_NN to_TO known_VBN genes_NNS and_CC ,_, more_RBR specifically_RB ,_, to_TO
          different_JJ stages_NNS of_IN breast_NN disease_NN is_VBZ still_RB under_IN
          investigation_NN ._. Studies_NNS in_IN benign_JJ fibroadenomas_NNS and_CC
          fibrocystic_JJ disease_NN showed_VBD no_DT LOH_NNP on_IN 1_CD p_NN ,_, 3_CD p_NN ,_, 7_CD q_NN ,_, 11_CD p_NN ,_,
          17_CD p_NN ,_, 17_CD q_NN or_CC 18_CD q_NN [_NN 7_CD ]_NN ._. However_RB ,_, 37_CD %_NN of_IN ductal_NN hyperplasias_NNS
          and_CC 42_CD %_NN of_IN atypical_JJ ductal_NN hyperplasias_NNS exhibit_NN LOH_NNP [_NN 8_CD ]_NN ,_,
          suggesting_VBG that_IN these_DT foci_NN are_VBP benign_JJ lesions_NNS resulting_VBG
          from_IN the_DT alteration_NN of_IN tumor_NN suppressor_NN genes_NNS ._.
          Furthermore_RB ,_, the_DT discovery_NN that_IN morphologically_RB normal_JJ
          terminal_NN duct-lobule_JJ units_NNS adjacent_JJ to_TO breast_NN cancers_NNS
          exhibit_NN LOH_NNP in_IN up_IN to_TO 60_CD %_NN of_IN cases_NNS when_WRB analyzed_VBD with_IN
          chromosome_NN 3_CD p_NN markers_NNS indicates_VBZ these_DT genetic_JJ events_NNS can_MD
          be_VB cryptically_RB present_JJ before_IN histopathological_JJ
          abnormalities_NNS are_VBP identifiable_JJ [_NN 9_CD ]_NN ._.
          These_DT aforementioned_JJ studies_NNS and_CC other_JJ research_NN
          support_NN the_DT idea_NN that_IN events_NNS affecting_VBG tumor_NN suppressors_NNS
          can_MD occur_VB early_JJ and_CC that_IN preinvasive_JJ DCIS_NNP can_MD be_VB a_DT direct_JJ
          precursor_NN of_IN invasive_JJ carcinoma_NN ,_, a_DT paradigm_NN supported_VBN
          pathologically_RB by_IN the_DT frequency_NN of_IN DCIS_NNP lesions_NNS found_VBD in_IN
          areas_NNS adjacent_JJ to_TO invasive_JJ breast_NN cancer_NN [_NN 10_CD ]_NN ._. These_DT
          same_JJ analyses_NNS also_RB confirm_VBP the_DT complexity_NN of_IN this_DT
          disease_NN ._. Examination_NNP of_IN multiple_JJ lesions_NNS from_IN individual_JJ
          tumors_NNS ,_, for_IN example_NN ,_, reveals_VBZ the_DT presence_NN of_IN intratumoral_NN
          heterogeneity_NN [_NN 11_CD ,_, 12_CD ,_, 13_CD ]_NN ._. Markers_NNP on_IN chromosome_NN 9_CD p_NN ,_, in_IN
          one_CD study_NN ,_, demonstrate_VB loss_NN of_IN opposite_JJ alleles_NNS in_IN
          different_JJ ducts_NNS while_IN examples_NNS of_IN ducts_NNS retaining_VBG both_DT
          alleles_NNS were_VBD also_RB found_VBN [_NN 14_CD ]_NN ._. An_DT extensive_JJ analysis_NN of_IN
          markers_NNS on_IN chromosome_NN 11_CD p_NN 15_CD showed_VBD LOH_NNP early_RB in_IN breast_NN
          disease_NN (_( DCIS_NNP )_) ,_, although_IN examples_NNS of_IN late_JJ stage_NN LOH_NNP
          without_IN concomittant_NN DCIS_NNP involvement_NN were_VBD also_RB found_VBN [_NN
          3_CD ]_NN ._. This_DT indicates_VBZ that_IN different_JJ components_NNS from_IN an_DT
          individual_JJ tumor_NN can_MD represent_VB genetically_RB divergent_JJ
          clones_NNS ,_, even_RB at_IN the_DT preinvasive_JJ stage_NN of_IN DCIS_NNP ._. The_DT
          heterogeneous_JJ nature_NN of_IN breast_NN cancer_NN alterations_NNS could_MD
          have_VB important_JJ implications_NNS for_IN the_DT development_NN of_IN
          targeted_VBN therapies_NNS ._.
          If_IN LOH_NNP events_NNS define_VB a_DT localized_JJ region_NN of_IN increased_VBN
          risk_NN for_IN carcinoma_NN ,_, the_DT presence_NN of_IN LOH_NNP may_MD be_VB clinically_RB
          important_JJ ._. A_DT complete_JJ understanding_NN of_IN all_PDT the_DT genetic_JJ
          events_NNS involved_VBN in_IN breast_NN tumorigenesis_NNS and_CC their_PRP$
          heterogeneity_NN in_IN relation_NN to_TO stage_VB specificity_NN will_MD
          therefore_RB be_VB critical_JJ to_TO the_DT development_NN of_IN successful_JJ
          treatments_NNS ._. This_DT laboratory_NN and_CC other_JJ workers_NNS have_VBP
          reported_VBN the_DT presence_NN of_IN a_DT previously_RB unidentified_JJ region_NN
          of_IN LOH_NNP in_IN band_NN 18_CD p_NN 11_CD ._. 3_LS in_IN non-small_JJ cell_NN lung_NN carcinomas_NNS ,_,
          glioblastomas_NNS and_CC a_DT small_JJ series_NN (_( 14_CD )_) of_IN invasive_JJ breast_NN
          carcinomas_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. The_DT current_JJ study_NN uses_VBZ informative_JJ
          loci_NN in_IN 18_CD p_NN 11_CD ._. 3_LS to_TO investigate_VB ,_, in_IN microdissected_JJ
          material_NN ,_, the_DT stage_NN specificity_NN and_CC extent_NN of_IN molecular_JJ
          heterogeneity_NN exhibited_VBN by_IN chromosome_NN 18_CD p_NN 11_CD in_IN breast_NN
          cancer_NN progression_NN ._. A_DT series_NN of_IN 30_CD tumors_NNS from_IN which_WDT 96_CD
          multiple_JJ stages_NNS of_IN disease_NN have_VBP been_VBN microdissected_JJ ,_,
          including_VBG normal_JJ ,_, DCIS_NNP and_CC IDC_NNP material_NN ,_, were_VBD studied_VBN ._.
          Associated_NNP metastases_NNS were_VBD also_RB examined_VBN in_IN some_DT cases_NNS ._.
          These_DT results_NNS were_VBD analyzed_VBN in_IN conjunction_NN with_IN other_JJ LOH_NNP
          data_NNS available_JJ for_IN markers_NNS on_IN 3_CD p_NN ,_, 11_CD p_NN ,_, 13_CD q_NN ,_, 16_CD p_NN ,_, 17_CD p_NN ,_, and_CC
          17_CD q_NN in_IN an_DT effort_NN to_TO place_VB chromosome_NN 18_CD p_NN alterations_NNS on_IN
          the_DT breast_NN cancer_NN progression_NN pathway_NN ._.
        
        
          Materials_NNS and_CC methods_NNS
          
            Patient_NNP material_NN
            The_DT material_NN used_VBN in_IN this_DT study_NN ,_, consisting_VBG of_IN
            formalin-fixed_JJ ,_, paraffin-embedded_JJ tissue_NN from_IN the_DT
            archives_NNS of_IN the_DT Armed_NNP Forces_NNP Institute_NNP of_IN Pathology_NNP ,_,
            has_VBZ been_VBN previously_RB described_VBN [_NN 3_CD ]_NN ._. Tumors_NNP were_VBD
            selected_VBN at_IN random_JJ for_IN those_DT with_IN the_DT presence_NN of_IN
            lesions_NNS representing_VBG multiple_JJ stages_NNS of_IN breast_NN disease_NN
            within_IN individual_JJ patient_NN samples_NNS ._. Ninety-six_NNP foci_NN
            representing_VBG normal_JJ ,_, intraductal_NN and_CC infiltrating_VBG tumor_NN
            were_VBD microdissected_JJ from_IN 30_CD tumors_NNS ._. One-half_NNP of_IN the_DT
            patient_NN samples_NNS contained_VBD both_DT DCIS_NNP and_CC IDC_NNP components_NNS ._.
            Seven_CD patients_NNS had_VBD metastatic_JJ tumor_NN tissue_NN available_JJ in_IN
            addition_NN to_TO both_DT DCIS_NNP and_CC IDC_NNP material_NN ,_, while_IN five_CD
            patients_NNS had_VBD invasive_JJ component_NN material_NN with_IN
            corresponding_JJ metastatic_JJ disease_NN ._. Aliquots_NNP of_IN DNA_NNP from_IN
            these_DT microdissected_JJ lesions_NNS were_VBD used_VBN as_IN the_DT source_NN
            template_NN for_IN PCR-based_NNP LOH_NNP analysis_NN ._.
          
          
            LOH_NNP analysis_NN
            Matching_NNP normal_JJ and_CC tumor_NN DNA_NNP were_VBD subjected_VBN to_TO
            PCR-based_NNP LOH_NNP analysis_NN using_VBG two_CD 18_CD p_NN 11_CD ._. 3_LS markers_NNS
            (_( D_NNP 18_CD S_NNP 59_CD and_CC D_NNP 18_CD S_NNP 481_CD )_) and_CC one_CD 18_CD p_NN 11_CD ._. 2_LS marker_NN (_( D_NNP 18_CD S_NNP 452_CD )_) ._.
            These_DT markers_NNS define_VB a_DT region_NN on_IN chromosome_NN 18_CD p_NN
            previously_RB shown_VBN to_TO undergo_VB LOH_NNP in_IN invasive_JJ ductal_NN
            breast_NN carcinomas_NNS as_RB well_RB as_IN non-small_JJ cell_NN lung_NN
            carcinomas_NNS and_CC glioblastomas_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. Forward_NNP primers_NNS
            were_VBD synthesized_JJ with_IN either_DT a_DT fluorescent_NN FAM_NNP tag_NN
            (_( D_NNP 18_CD S_NNP 481_CD and_CC D_NNP 18_CD S_NNP 452_CD )_) or_CC a_DT fluorescent_NN TET_NNP tag_NN (_( D_NNP 18_CD S_NNP 59_CD )_)
            on_IN the_DT 5_CD '_POS end_NN ._. PCR_NNP reactions_NNS were_VBD performed_VBN in_IN 10_CD μl_NN
            with_IN aliquots_NNS of_IN normal_JJ and_CC tumor_NN DNA_NNP using_VBG a_DT PCR_NNP
            protocol_NN consisting_VBG of_IN 94_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_, 55_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_,
            and_CC 72_CD °_NN C_NNP for_IN 1_CD min_NN for_IN a_DT total_NN of_IN 40_CD cycles_NNS ._.
          
          
            Horizontal_NNP ultrathin_NN gel_NN electrophoresis_NNS
            Horizontal_NNP ultrathin_NN ,_, high_JJ throughput_NN
            fluorescence-based_JJ DNA_NNP fragment_NN gel_NN electrophoresis_NNS
            (_( GTI-_NNP 9600_CD ;_: Genesys_NNP Technologies_NNPS ,_, Inc_NNP )_) was_VBD applied_VBN to_TO
            the_DT separation_NN and_CC analysis_NN of_IN PCR-generated_NNP alleles_NNS as_RB
            previously_RB described_VBD [_NN 4_CD ]_NN ._. One_CD microliter_NN of_IN amplified_VBN
            material_NN was_VBD combined_VBN with_IN 2_CD μl_NN formamide_NN loading_NN dye_NN
            (_( Amersham_NNP Inc_NNP ,_, Piscat-away_NNP ,_, NJ_NNP ,_, USA_NNP )_) prior_RB to_TO
            electrophoresis_NNS ._. ROX_NNP 350_CD fluorescent_NN size_NN markers_NNS (_( 0_CD ._. 7_CD
            μl_NN ;_: ABI_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP ,_, USA_NNP )_) were_VBD added_VBN to_TO amplified_VBN
            tumor_NN DNA_NNP to_TO allow_VB sizing_VBG of_IN alleles_NNS ._. Samples_NNP were_VBD
            heated_VBN to_TO 95_CD °_NN C_NNP ,_, loaded_VBN on_IN the_DT 70_CD μm_NN ,_, 5_CD %_NN horizontal_NN
            polyacrylamide_NN gel_NN and_CC electrophoresed_JJ for_IN 1_CD h_NN and_CC 15_CD
            min_NN at_IN 30_CD W_NNP in_IN 1_CD ×_NN TBE_NNP using_VBG the_DT GTI-_NNP 9600_CD ._. Data_NNP were_VBD
            collected_VBN while_IN running_VBG the_DT electrophoresis_NNS and_CC stored_VBD
            using_VBG the_DT accompanying_VBG Cartographer_NNP data_NNS analysis_NN
            software_NN program_NN ,_, which_WDT extracts_NNS the_DT pixel_NN intensity_NN of_IN
            individual_JJ peaks_NNS present_JJ in_IN a_DT lane_NN trace_VB ,_, allowing_VBG for_IN
            sizing_VBG of_IN alleles_NNS and_CC quantitation_NN of_IN fluorescent_NN peak_NN
            areas_NNS ._. In_IN determining_VBG whether_IN allelic_JJ deletion_NN had_VBD
            occurred_VBN at_IN individual_JJ markers_NNS ,_, allelic_JJ ratios_NNS were_VBD
            calculated_VBN and_CC expressed_VBN as_IN a_DT percentage_NN of_IN loss_NN of_IN
            intensity_NN for_IN the_DT tumor_NN allele_NN compared_VBN with_IN the_DT
            corresponding_JJ normal_JJ allele_NN (_( D-_NNP value_NN )_) after_IN
            normalization_NN ._. When_WRB the_DT allelic_JJ ratio_NN in_IN the_DT tumor_NN DNA_NNP
            was_VBD reduced_VBN by_IN greater_JJR than_IN 40_CD %_NN (_( DO_NNP ._. 40_CD )_) from_IN that_DT found_VBD
            in_IN the_DT normal_JJ DNA_NNP ,_, the_DT sample_NN was_VBD denoted_JJ as_IN having_VBG LOH_NNP
            at_IN that_DT locus_JJ ._.
          
        
        
          Results_NNS
          
            Chromosome_NNP 18_CD p_NN 11_CD LOH_NNP in_IN breast_NN cancer_NN
            progression_NN
            A_DT total_NN of_IN 96_CD foci_NN were_VBD individually_RB microdissected_JJ
            from_IN 30_CD breast_NN tumor_NN cases_NNS and_CC analyzed_VBD for_IN LOH_NNP at_IN the_DT
            polymorphic_JJ markers_NNS D_NNP 18_CD S_NNP 59_CD and_CC D_NNP 18_CD S_NNP 481_CD spanning_VBG
            18_CD p_NN 11_CD ._. 3_LS ._. These_DT microdissections_NNS resulted_VBD in_IN normal_JJ ,_,
            DCIS_NNP and_CC IDC_NNP material_NN from_IN most_JJS tumors_NNS ._. The_DT overall_JJ
            frequency_NN of_IN LOH_NNP in_IN 18_CD p_NN 11_CD ._. 3_LS ,_, as_IN measured_VBN for_IN any_DT stage_NN
            of_IN disease_NN using_VBG D_NNP 18_CD S_NNP 481_CD and_CC /_NN or_CC D_NNP 18_CD S_NNP 59_CD ,_, was_VBD 63_CD %_NN
            (_( 27_CD /_NN 43_CD )_) ._. This_DT is_VBZ significantly_RB higher_JJR than_IN the_DT 21_CD %_NN
            frequency_NN originally_RB reported_VBD using_VBG non-microdissected_JJ
            IDC_NNP samples_NNS [_NN 1_CD ]_NN ,_, suggesting_VBG that_IN allelic_JJ deletion_NN
            events_NNS may_MD have_VB been_VBN masked_VBN by_IN contaminating_VBG normal_JJ
            stroma_NN in_IN earlier_JJR studies_NNS ._. A_DT low_JJ frequency_NN (_( 3_CD /_NN 96_CD )_) of_IN
            microsatellite_NN instability_NN was_VBD also_RB detected_VBN at_IN marker_NN
            D_NNP 18_CD S_NNP 59_CD ._. These_DT microsatellite_NN instability_NN results_NNS were_VBD
            confirmed_VBN in_IN at_IN least_JJS two_CD independent_JJ experiments_NNS and_CC
            correspond_VB to_TO previous_JJ published_VBN results_NNS for_IN this_DT
            marker_NN [_NN 2_CD ]_NN ._.
            LOH_NNP on_IN 18_CD p_NN was_VBD found_VBN ,_, when_WRB analyzed_VBN by_IN tumor_NN stage_NN ,_,
            in_IN 56_CD %_NN (_( 9_CD /_NN 16_CD )_) of_IN DCIS_NNP foci_NN ,_, 67_CD %_NN of_IN IDC_NNP foci_NN (_( 14_CD /_NN 21_CD )_) ,_,
            and_CC 67_CD %_NN (_( 4_CD /_NN 6_CD )_) of_IN metastatic_JJ disease_NN ._. A_DT schematic_JJ
            representation_NN of_IN all_DT tumor_NN foci_NN studied_VBN appears_VBZ in_IN
            Figure_NN 1_CD ._. The_DT magnitude_NN of_IN LOH_NNP detected_VBD indicates_VBZ that_IN
            alterations_NNS in_IN this_DT region_NN generally_RB occur_VB early_RB in_IN
            breast_NN cancer_NN progression_NN ._. In_IN four_CD cases_NNS (_( cases_NNS 6_CD ,_, 18_CD ,_,
            27_CD ,_, and_CC 28_CD )_) ,_, however_RB ,_, LOH_NNP was_VBD not_RB detected_VBN until_IN the_DT
            invasive_JJ stage_NN ,_, and_CC in_IN two_CD cases_NNS (_( cases_NNS 1_CD and_CC 2_LS )_) LOH_NNP
            was_VBD only_RB detected_VBN in_IN metastatic_JJ disease_NN (_( Fig_NNP ._. 1_LS )_) ._. This_DT
            suggests_VBZ that_IN allelic_JJ deletion_NN in_IN 18_CD p_NN 11_CD ._. 3_LS may_MD also_RB
            arise_VB late_RB in_IN progression_NN ,_, albeit_IN with_IN less_JJR frequency_NN ._.
            Such_JJ heterogeneity_NN in_IN the_DT stage_NN specificity_NN of_IN genetic_JJ
            events_NNS has_VBZ also_RB been_VBN shown_VBN for_IN other_JJ chromosomal_NN
            regions_NNS harboring_VBG tumor_NN suppressor_NN loci_NN [_NN 11_CD ,_, 12_CD ,_,
            13_CD ]_NN ._.
            The_DT extent_NN to_TO which_WDT LOH_NNP is_VBZ specific_JJ to_TO band_VB 18_CD p_NN 11_CD ._. 3_LS
            was_VBD determined_VBN by_IN analysis_NN with_IN marker_NN D_NNP 18_CD S_NNP 452_CD ._. This_DT
            marker_NN resides_VBZ at_IN the_DT border_NN between_IN bands_NNS 18_CD p_NN 11_CD ._. 3_LS and_CC
            18_CD p_NN 11_CD ._. 2_LS ,_, approximately_RB 12_CD cM_NN proximal_NN to_TO D_NNP 18_CD S_NNP 481_CD ._. Of_IN
            the_DT 15_CD tumor_NN foci_NN with_IN LOH_NNP at_IN 18_CD p_NN 11_CD ._. 3_LS and_CC for_IN which_WDT
            D_NNP 18_CD S_NNP 452_CD was_VBD informative_JJ ,_, 73_CD %_NN (_( 11_CD /_NN 15_CD )_) retained_VBD
            heterozygosity_NN at_IN this_DT 18_CD p_NN 11_CD ._. 2_LS marker_NN ._. The_DT majority_NN of_IN
            measured_VBN deletion_NN events_NNS being_VBG detected_VBN are_VBP thus_RB
            intrachromosomal_NN events_NNS rather_RB than_IN loss_NN of_IN the_DT entire_JJ
            chromosome_NN 18_CD ._.
          
          
            Heterogeneity_NNP of_IN 18_CD p_NN LOH_NNP in_IN breast_NN cancer_NN
            progression_NN
            Previous_JJ genetic_JJ studies_NNS have_VBP shown_VBN that_IN
            heterogeneous_JJ pathways_NNS exist_VBP for_IN breast_NN cancer_NN
            progression_NN [_NN 15_CD ,_, 16_CD ]_NN ._. We_PRP could_MD examine_VB ,_, by_IN studying_VBG
            multistage_NN individually_RB microdissected_JJ tumor_NN components_NNS
            from_IN the_DT same_JJ specimen_NN ,_, the_DT extent_NN of_IN heterogeneity_NN
            associated_VBN with_IN chromosome_NN 18_CD p_NN LOH_NNP (_( Fig_NNP ._. 2_LS )_) ._. In_IN tumors_NNS
            where_WRB allelic_JJ loss_NN information_NN was_VBD attainable_JJ for_IN two_CD
            or_CC more_JJR disease_NN stages_NNS ,_, 73_CD %_NN (_( 11_CD /_NN 15_CD )_) displayed_VBD a_DT pattern_NN
            of_IN LOH_NNP indicative_JJ of_IN a_DT classic_JJ clonal_NN progression_NN ._. LOH_NNP
            first_RB appeared_VBD in_IN the_DT DCIS_NNP stage_NN for_IN the_DT majority_NN of_IN
            these_DT cases_NNS (_( cases_NNS 3_CD ,_, 9_CD ,_, 31_CD ,_, 39_CD ,_, 47_CD ,_, 51_CD and_CC 53_CD )_) ._. Four_CD
            tumors_NNS were_VBD ,_, however_RB ,_, interestingly_RB identified_VBN with_IN
            genetic_JJ heterogeneity_NN for_IN chromosome_NN 18_CD p_NN events_NNS ._. LOH_NNP
            detected_VBD in_IN the_DT DCIS_NNP component_NN was_VBD not_RB found_VBN in_IN the_DT
            associated_VBN IDC_NNP component_NN in_IN two_CD cases_NNS (_( tumors_NNS 21_CD and_CC
            44_CD )_) ,_, suggesting_VBG that_IN the_DT invasive_JJ foci_NN arose_VBD from_IN cells_NNS
            other_JJ than_IN those_DT associated_VBN with_IN the_DT analyzed_VBN DCIS_NNP
            focus_VB ._. Microsatellite_NNP instability_NN and_CC LOH_NNP distinguish_VB
            multiple_JJ pathways_NNS of_IN progression_NN in_IN the_DT remaining_VBG two_CD
            tumors_NNS (_( cases_NNS 2_CD and_CC 27_CD )_) ._. Thus_RB ,_, although_IN genetic_JJ events_NNS
            involving_VBG chromosome_NN 18_CD p_NN sequences_NNS most_RBS often_RB follow_VB a_DT
            classic_JJ progression_NN paradigm_NN ,_, a_DT significant_JJ proportion_NN
            (_( 27_CD %_NN )_) do_VBP not_RB ._.
          
          
            Correlations_NNP of_IN allelic_JJ loss_NN in_IN chromosome_NN
            18_CD p_NN
            Realizing_NNP that_DT loss_NN on_IN 18_CD p_NN is_VBZ only_RB one_CD part_NN of_IN the_DT
            complex_JJ genetic_JJ profile_NN for_IN breast_NN cancer_NN ,_, we_PRP sought_VBD to_TO
            discover_VB whether_IN genetic_JJ alteration_NN on_IN this_DT chromosome_NN
            correlated_JJ with_IN LOH_NNP in_IN other_JJ regions_NNS known_VBN to_TO undergo_VB
            allelic_JJ deletion_NN in_IN cancer_NN ._. These_DT tumors_NNS had_VBD previously_RB
            been_VBN shown_VBN to_TO have_VB undergone_VBN allelic_JJ deletion_NN on_IN
            chromosomes_NNS 3_CD p_NN (_( 77_CD %_NN )_) ,_, 9_CD p_NN (_( 75_CD %_NN )_) ,_, 11_CD p_NN (_( 37_CD %_NN )_) ,_, 13_CD q_NN (_( 39_CD %_NN )_) ,_,
            16_CD q_NN (_( 85_CD %_NN )_) ,_, 17_CD p_NN (_( 100_CD %_NN )_) and_CC 17_CD q_NN (_( 71_CD %_NN )_) ._. The_DT LOH_NNP results_NNS
            specifically_RB for_IN those_DT tumors_NNS also_RB showing_VBG detectable_JJ
            chromosome_NN 18_CD p_NN LOH_NNP are_VBP presented_VBN in_IN Figure_NN 3_CD ._. In_IN every_DT
            instance_NN where_WRB information_NN was_VBD available_JJ ,_, LOH_NNP on_IN
            chromosomes_NNS 3_CD p_NN (_( region_NN C_NNP 13_CD -_: CA_NNP 373_CD -_: D_NNP 3_CD S_NNP 1300_CD )_) ,_, 9_CD p_NN (_( region_NN
            D_NNP 9_CD S_NNP 171_CD -_: D_NNP 9_CD S_NNP 1748_CD )_) ,_, 17_CD p_NN (_( region_NN D_NNP 17_CD S_NNP 1832_CD -_: D_NNP 17_CD S_NNP 1788_CD
            including_VBG p_NN 53_CD )_) and_CC 17_CD q_NN (_( region_NN THRA_NNP 1_CD -_: D_NNP 17_CD S_NNP 928_CD including_VBG
            nm_NN 23_CD )_) was_VBD present_JJ when_WRB 18_CD p_NN LOH_NNP occurred_VBD ._. Chromosome_NNP 16_CD q_NN
            LOH_NNP (_( region_NN D_NNP 16_CD S_NNP 496_CD -_: D_NNP 16_CD S_NNP 513_CD )_) ,_, in_IN contrast_NN ,_, was_VBD only_RB
            found_VBN in_IN 81_CD %_NN ,_, chromosome_NN 13_CD q_NN (_( D_NNP 13_CD S_NNP 260_CD -_: D_NNP 13_CD S_NNP 263_CD )_) in_IN 55_CD %_NN ,_,
            and_CC chromosome_NN 11_CD p_NN (_( region_NN D_NNP 11_CD S_NNP 922_CD -_: D_NNP 11_CD S_NNP 988_CD including_VBG
            TH_NNP )_) in_IN 48_CD %_NN of_IN tumors_NNS also_RB having_VBG 18_CD p_NN LOH_NNP ._. These_DT
            frequencies_NNS suggest_VBP that_IN alterations_NNS on_IN chromosome_NN 18_CD p_NN
            occur_VB more_RBR often_RB in_IN the_DT presence_NN of_IN alterations_NNS
            affecting_VBG regions_NNS containing_VBG such_JJ tumor_NN suppressors_NNS as_IN
            p_NN 16_CD (_( 9_CD p_NN )_) [_NN 17_CD ]_NN and_CC p_NN 53_CD (_( 17_CD p_NN )_) [_NN 18_CD ]_NN ,_, while_IN events_NNS on_IN
            chromosomes_NNS 13_CD q_NN ,_, 16_CD q_NN and_CC 11_CD p_NN occur_VB more_RBR
            independently_RB ._.
          
        
        
          Discussion_NNP
          Current_JJ knowledge_NN about_IN the_DT progression_NN of_IN breast_NN
          cancer_NN reveals_VBZ that_IN ,_, by_IN analogy_NN to_TO colon_NN and_CC brain_NN
          tumors_NNS ,_, genetic_JJ aberrations_NNS can_MD occur_VB in_IN a_DT disease_NN stage_NN
          or_CC grade_NN specific_JJ manner_NN ._. Clonal_NNP evolution_NN is_VBZ ,_, however_RB ,_, a_DT
          dynamic_JJ process_NN from_IN which_WDT clones_NNS that_WDT are_VBP not_RB
          necessarily_RB committed_VBN to_TO a_DT malignant_JJ phenotype_NN can_MD also_RB
          emerge_VB ,_, resulting_VBG in_IN genetic_JJ heterogeneity_NN in_IN the_DT tissue_NN ._.
          Such_JJ genetic_JJ heterogeneity_NN has_VBZ been_VBN described_VBN for_IN
          multiple_JJ loci_NN in_IN breast_NN cancer_NN [_NN 3_CD ,_, 11_CD ,_, 16_CD ,_, 19_CD ,_, 20_CD ]_NN ,_,
          providing_VBG an_DT understanding_NN of_IN the_DT complex_JJ picture_NN of_IN
          breast_NN cancer_NN pathogenesis_NNS ._. Such_JJ an_DT understanding_NN is_VBZ
          necessary_JJ if_IN detection_NN of_IN LOH_NNP or_CC other_JJ genetic_JJ
          abnormalities_NNS will_MD ever_RB allow_VB for_IN consistent_JJ and_CC useful_JJ
          identification_NN of_IN preinvasive_JJ breast_NN lesions_NNS at_IN higher_JJR
          risk_NN of_IN progression_NN ._.
          The_DT present_JJ study_NN investigated_VBD stage_NN specificity_NN and_CC
          level_NN of_IN genetic_JJ heterogeneity_NN of_IN LOH_NNP events_NNS in_IN a_DT new_JJ
          region_NN (_( 18_CD p_NN 11_CD ._. 3_LS )_) involved_VBN in_IN breast_NN cancer_NN ._. Significant_JJ
          LOH_NNP for_IN chromosome_NN 18_CD p_NN 11_CD ._. 3_LS (_( 63_CD %_NN )_) was_VBD discovered_VBN using_VBG
          microdissected_JJ foci_NN ,_, suggesting_VBG the_DT presence_NN of_IN a_DT
          putative_JJ tumor_NN suppressor_NN gene_NN (_( s_VBZ )_) on_IN 18_CD p_NN with_IN an_DT
          important_JJ role_NN in_IN the_DT pathogenesis_NNS of_IN breast_NN cancer_NN ._. The_DT
          frequency_NN reported_VBD in_IN the_DT present_JJ study_NN (_( 63_CD %_NN )_) is_VBZ
          significantly_RB higher_JJR than_IN the_DT original_NN reported_JJ frequency_NN
          of_IN 21_CD %_NN [_NN 1_CD ]_NN and_CC most_RBS probably_RB reflects_VBZ the_DT superior_JJ
          separation_NN of_IN tumor_NN cells_NNS from_IN normal_JJ contaminating_VBG
          tissue_NN using_VBG a_DT microdissection_NN protocol_NN ._. A_DT series_NN of_IN
          unrelated_JJ microdissected_JJ DCIS_NNP tumors_NNS for_IN which_WDT no_DT
          invasive_JJ component_NN was_VBD present_JJ also_RB show_NN this_DT high_JJ LOH_NNP
          frequency_NN (_( 58_CD %_NN )_) when_WRB measured_VBN at_IN 18_CD p_NN 11_CD ._. 3_LS (_( data_NNS not_RB
          shown_VBN )_) ,_, suggesting_VBG the_DT 63_CD %_NN frequency_NN reported_VBD in_IN the_DT
          present_JJ study_NN is_VBZ not_RB a_DT consequence_NN of_IN analyzing_VBG samples_NNS
          containing_VBG multiple_JJ stages_NNS of_IN disease_NN ._. These_DT measured_VBN
          allelic_JJ deletions_NNS represent_VBP alterations_NNS specific_JJ to_TO
          18_CD p_NN 11_CD ._. 3_LS and_CC not_RB entire_JJ chromosome_NN 18_CD events_NNS based_VBN on_IN
          results_NNS using_VBG marker_NN D_NNP 18_CD S_NNP 452_CD ,_, although_IN the_DT presence_NN of_IN
          simultaneous_JJ but_CC independent_JJ LOH_NNP on_IN 18_CD q_NN was_VBD not_RB
          examined_VBN ._.
          It_PRP was_VBD discovered_VBN ,_, by_IN analyzing_VBG multiple_JJ foci_NN
          occurring_VBG simultaneously_RB within_IN individual_JJ tumors_NNS ,_, that_DT
          chromosome_NN 18_CD p_NN events_NNS occur_VBP at_IN a_DT significant_JJ frequency_NN
          (_( 56_CD %_NN )_) early_RB in_IN the_DT tumorigenic_JJ process_NN ,_, making_VBG LOH_NNP at_IN
          chromosome_NN 18_CD p_NN one_CD of_IN the_DT most_RBS common_JJ known_VBN events_NNS in_IN
          DCIS_NNP tumors_NNS ._. For_IN 73_CD %_NN of_IN the_DT cases_NNS in_IN which_WDT multiple_JJ
          stages_NNS of_IN disease_NN arose_VBD simultaneously_RB and_CC for_IN which_WDT
          information_NN on_IN at_IN least_JJS one_CD marker_NN was_VBD available_JJ ,_, 18_CD p_NN 11_CD ._. 3_LS
          LOH_NNP in_IN the_DT DCIS_NNP component_NN could_MD also_RB be_VB found_VBN in_IN the_DT
          invasive_JJ component_NN isolated_VBN for_IN analysis_NN (_( Fig_NNP ._. 2_LS )_) ._. This_DT
          suggests_VBZ that_IN the_DT majority_NN of_IN breast_NN tumors_NNS progress_NN in_IN a_DT
          clonal_NN fashion_NN ._. Four_CD cases_NNS (_( 27_CD %_NN )_) were_VBD ,_, however_RB ,_,
          consistent_JJ with_IN genetic_JJ heterogeneity_NN at_IN this_DT chromosomal_NN
          region_NN ._. These_DT latter_JJ observations_NNS argue_VBP that_IN invasive_JJ
          foci_NN of_IN an_DT individual_JJ tumor_NN can_MD represent_VB genetically_RB
          divergent_JJ clones_NNS rather_RB than_IN progressive_JJ stages_NNS of_IN the_DT
          disease_NN ._. Such_JJ conclusions_NNS are_VBP further_RBR supported_VBN by_IN flow_NN
          cytometric_JJ and_CC comparative_JJ genomic_JJ hybridization_NN analyses_NNS
          on_IN primary_JJ and_CC metastatic_JJ disease_NN components_NNS [_NN 19_CD ,_, 20_CD ]_NN ._.
          In_IN the_DT comparative_JJ genomic_JJ hybridization_NN study_NN [_NN 20_CD ]_NN ,_, 69_CD %_NN
          of_IN metastatic_JJ lesions_NNS showed_VBD a_DT high_JJ degree_NN of_IN clonal_NN
          progression_NN from_IN the_DT primary_JJ tumor_NN ,_, whereas_IN 31_CD %_NN did_VBD not_RB ._.
          These_DT frequencies_NNS parallel_VB the_DT 70_CD %_NN clonal_NN /_NN 30_CD %_NN
          heterogeneous_JJ progression_NN frequencies_NNS reported_VBD for_IN
          chromosome_NN 18_CD p_NN events_NNS in_IN the_DT present_JJ study_NN ._.
          We_PRP are_VBP not_RB yet_RB at_IN a_DT stage_NN in_IN our_PRP$ understanding_NN of_IN
          breast_NN disease_NN such_JJ that_IN genetic_JJ alterations_NNS can_MD
          substitute_VB for_IN the_DT histopathology_NN of_IN the_DT lesion_NN ._. A_DT
          combinatorial_NN histological_JJ and_CC genetic_JJ approach_NN with_IN
          sufficient_JJ information_NN on_IN survival_NN and_CC response_NN profiles_NNS
          may_MD ,_, however_RB ,_, make_VB for_IN more_RBR effective_JJ disease_NN prevention_NN
          and_CC cure_VB in_IN the_DT future_NN ._. The_DT power_NN of_IN genetic_JJ profiles_NNS in_IN
          prognostic_JJ relevance_NN has_VBZ recently_RB been_VBN shown_VBN by_IN Emi_NNP 
          et_CC al_NN [_NN 21_CD ]_NN ._. Studying_NNP 15_CD loci_NN in_IN
          264_CD women_NNS ,_, Emi_NNP 
          et_CC al_NN found_VBD that_IN LOH_NNP at_IN markers_NNS
          1_CD p_NN 34_CD ,_, 13_CD q_NN 12_CD ,_, 17_CD p_NN 13_CD ._. 3_LS and_CC 17_CD q_NN 21_CD ._. 1_LS ,_, as_RB well_RB as_IN two_CD pairs_NNS of_IN
          markers_NNS (_( 1_CD p_NN 34_CD /_NN 17_CD p_NN 13_CD ._. 3_LS and_CC 13_CD q_NN 12_CD /_NN 17_CD p_NN 13_CD ._. 3_LS )_) ,_, had_VBD significant_JJ
          prognostic_JJ value_NN and_CC carried_VBD significant_JJ relative_JJ risk_NN of_IN
          death_NN ._. It_PRP would_MD be_VB interesting_JJ ,_, given_VBN the_DT high_JJ frequency_NN
          of_IN LOH_NNP discovered_VBD for_IN chromosomal_NN region_NN 18_CD p_NN 11_CD ._. 3_LS in_IN this_DT
          report_NN ,_, to_TO include_VB this_DT marker_NN along_IN with_IN these_DT regions_NNS
          to_TO determine_VB its_PRP$ usefulness_NN as_IN a_DT predictive_JJ risk_NN marker_NN
          in_IN breast_NN cancer_NN ._.
          To_TO that_DT extent_NN ,_, it_PRP was_VBD interesting_JJ to_TO view_VB a_DT partial_JJ
          genetic_JJ profile_NN for_IN other_JJ regions_NNS of_IN LOH_NNP in_IN these_DT tumors_NNS
          when_WRB chromosome_NN 18_CD LOH_NNP was_VBD present_JJ ._. Chromosome_NNP 18_CD p_NN LOH_NNP
          always_RB occurred_VBD in_IN conjunction_NN with_IN LOH_NNP on_IN 3_CD p_NN ,_, 9_CD p_NN ,_, 17_CD p_NN
          and_CC 17_CD q_NN independent_JJ of_IN tumor_NN stage_NN ,_, suggesting_VBG this_DT group_NN
          of_IN loci_NN were_VBD critical_JJ to_TO the_DT development_NN of_IN breast_NN
          cancer_NN ._. Allelic_NNP deletion_NN on_IN chromosomes_NNS 16_CD q_NN ,_, 13_CD q_NN and_CC 11_CD p_NN
          occurred_VBD less_RBR consistently_RB (_( 81_CD ,_, 55_CD and_CC 46_CD %_NN ,_,
          respectively_RB )_) ,_, suggesting_VBG these_DT regional_JJ events_NNS are_VBP more_JJR
          varied_VBN depending_VBG on_IN the_DT stage_NN and_CC /_NN or_CC type_NN of_IN tumor_NN foci_NN
          analyzed_VBD ._. Of_IN further_JJ interest_NN is_VBZ the_DT putative_JJ tumor_NN
          suppressor_NN gene_NN ,_, DAL-_NNP 1_CD ,_, which_WDT has_VBZ recently_RB been_VBN mapped_VBN to_TO
          chromosome_NN band_NN 18_CD p_NN 11_CD ._. 3_LS [_NN 22_CD ]_NN ._. It_PRP will_MD be_VB important_JJ to_TO
          learn_VB more_JJR about_IN the_DT function_NN of_IN this_DT gene_NN and_CC its_PRP$
          potential_JJ mutational_NN profile_NN in_IN breast_NN cancer_NN ._. Future_JJ
          studies_NNS will_MD determine_VB whether_IN this_DT or_CC another_DT tumor_NN
          suppressor_NN gene_NN is_VBZ the_DT target_NN of_IN the_DT high_JJ frequency_NN of_IN
          allelic_JJ deletion_NN measured_VBN in_IN this_DT study_NN for_IN breast_NN
          cancer_NN ._.
        
      
      
        Abbreviations_NNP
        DCIS_NNP =_SYM ductal_NN carcinoma_NN 
        in_IN situ_NN ;_: IDC_NNP =_SYM invasive_JJ ductal_NN
        carcinoma_NN ;_: LOH_NNP =_SYM loss_NN of_IN heterozygosity_NN ;_: PCR_NNP =_SYM polymerase_NN
        chain_NN reaction_NN ._.
      
    
  
